U.S. License Holder:
Date of License:
RITUXAN HYCELA (hyaluronidase; rituximab) is a combination of rituximab, a CD20 directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
Follicular Lymphoma (FL): Relapsed or refractory, follicular lymphoma as a single agent; Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy; Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy;
Diffuse Large B-cell Lymphoma (DLBCL): Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens;
Chronic Lymphocytic Leukemia (CLL): Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC).